small molecule modulator of smn2 splicing (Novartis)
Structured Review
Small Molecule Modulator Of Smn2 Splicing, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+molecule+modulator+of+smn2+splicing/smn2++splicing+modulator/10__1016_slash_b978___0___12___803685___3__00016___1-103-11-26
Average 90 stars, based on 1 article reviews
Images
Related Articles
Mutagenesis:Article Title: Spinal Muscular Atrophy Therapeutics Development Article Snippet: http://dx.doi.org/10.1016/B978-0-12-803685-3.00016-1 © 2017 Elsevier Inc. All rights reserved.. 263 There have been significant advances in our understanding of the genetic, biologic, and cellular mechanisms underlying spinal muscular atrophy (SMA) since the disease-causing genetic defect was identified in 1995.. The establishment of robust assays, biomarker panels, and animal models representing a spectrum of disease severity has enabled important insights into SMA pathophysiology and facilitated preclinical therapeutic development. Nuclear Magnetic Resonance:Article Title: Spinal Muscular Atrophy Therapeutics Development Article Snippet: http://dx.doi.org/10.1016/B978-0-12-803685-3.00016-1 © 2017 Elsevier Inc. All rights reserved.. 263 There have been significant advances in our understanding of the genetic, biologic, and cellular mechanisms underlying spinal muscular atrophy (SMA) since the disease-causing genetic defect was identified in 1995.. The establishment of robust assays, biomarker panels, and animal models representing a spectrum of disease severity has enabled important insights into SMA pathophysiology and facilitated preclinical therapeutic development. Spectroscopy:Article Title: Spinal Muscular Atrophy Therapeutics Development Article Snippet: http://dx.doi.org/10.1016/B978-0-12-803685-3.00016-1 © 2017 Elsevier Inc. All rights reserved.. 263 There have been significant advances in our understanding of the genetic, biologic, and cellular mechanisms underlying spinal muscular atrophy (SMA) since the disease-causing genetic defect was identified in 1995.. The establishment of robust assays, biomarker panels, and animal models representing a spectrum of disease severity has enabled important insights into SMA pathophysiology and facilitated preclinical therapeutic development. Binding Assay:Article Title: Spinal Muscular Atrophy Therapeutics Development Article Snippet: http://dx.doi.org/10.1016/B978-0-12-803685-3.00016-1 © 2017 Elsevier Inc. All rights reserved.. 263 There have been significant advances in our understanding of the genetic, biologic, and cellular mechanisms underlying spinal muscular atrophy (SMA) since the disease-causing genetic defect was identified in 1995.. The establishment of robust assays, biomarker panels, and animal models representing a spectrum of disease severity has enabled important insights into SMA pathophysiology and facilitated preclinical therapeutic development. |
